Neumann Discusses Cures Act and New FDA Draft Guidance on Communication

In his latest Health Affairs blog posting, PHE Scientific Advisor Peter Neumann and co-author Elle Pope examine Section 3037 of the Cures Act and new FDA draft guidance, which indicate that drug companies will have expanded flexibility to communicate proactively with payors and formulary committees about the real-world impacts of their products.

To read Dr. Neumann's blog, please click here.